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Abstract
Cancer-related fatigue (CRF) is a major and very common disabling condition in cancer patients.
Treatment options do exist but have limited therapeutic effects. Mistletoe extracts are widely-used
complementary cancer treatments whose possible impact on CRF has not been investigated in
detail. A 36-year-old Swedish woman with a 10-year history of recurrent breast cancer, suffering
from severe CRF, started complementary cancer treatment with mistletoe extracts. Over two and
a half years a correspondence was observed between the intensity of mistletoe therapy and the
fatigue. Mistletoe extracts seemed to have a beneficial, dose-dependent effect on CRF. Although
such effect has also been noted in clinical studies, it has never been the subject of detailed
investigation. More research should clarify these observations.
Introduction
Cancer-related fatigue (CRF) is a highly prevalent condi-
tion in cancer patients at all stages. It is a most distressing
symptom that substantially impairs quality of life (QoL)
and physical and emotional functioning. It disrupts daily
activities and has a substantial economic impact. [1-3] It
is characterized by persistent tiredness disproportionate
to activity, and an increased need to rest; a sustained sense
of exhaustion that cannot be completely relieved by rest;
and diminished energy, mental capacity, and psychologi-
cal status [4,5]. Causes are poorly understood and
research lags far behind research activities on other can-
cer-related topics. [1,3] Factors that contribute to its devel-
opment are: cancer type and cancer treatment, length of
time after treatment, other medications, anemia, sleep
disorders, nutrition problems, pain, activity level, psycho-
social factors and others [6]. CRF can persist for years and
is also common in disease-free cancer patients (D-FCP)
with a prevalence of up to 41% in breast-cancer patients
[7,8]. CRF in D-FCP seems to be more closely connected
with psychosocial factors (psychological distress, sleep
disorders, level of activity) than to cancer type, cancer
treatment and length of time after treatment. Recently a
correlation with raised levels of pro-inflammatory
cytokines was observed [9]. Hitherto, fatigue has not been
regarded as a risk factor for relapse; however, a recent
report described low fatigue to be a predictor for longer
recurrence-free survival in breast-cancer patients [10].
Therapeutic options are limited. Physical exercise, cogni-
tive therapy and medication can have some beneficial
effects [11,12] but seem not to provide sufficient relief,
and many patients have a sense of resignation regarding
the alleviation of their fatigue [2,3].
Cancer patients often use complementary and alternative
medicine (CAM). Among the most frequently applied
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CAM therapies for cancer are aqueous extracts from Euro-
pean mistletoe (Viscum album L.), originally developed as
a cancer remedy in the context of anthroposophic medi-
cine (AM) [13,14]. Biological properties have been exten-
sively analyzed and several pharmacologically active
compounds isolated. Mistletoe extracts show highly cyto-
toxic and growth-inhibiting effects, especially through
induction of apoptosis, but they also possess DNA-stabi-
lizing properties in mononuclear cells; they stimulate the
immune system (in vivo and in vitro activation of mono-
cytes/macrophages, granulocytes, natural killer cells, T-
cells, induction of a variety of cytokines) and can enhance
endorphins. [13,15] Injected in tumor-bearing animals,
they display growth-inhibiting and tumor-reducing
effects. [13,15] Mistletoe remedies, either alone or in com-
bination with surgery, chemotherapy, radiation or hor-
mone therapy, are applied in all cancer types and all stages
of disease, in order to improve QoL and general condi-
tion, to reduce side effects of oncological treatment and to
improve immuno-suppression, and prolong time to pro-
gression and survival. [13] Controlled clinical trials found
best evidence of efficacy in relation to improvement of
QoL and reduction of side effects of chemotherapy and
radiation. Most trials also observed survival benefit, but
not beyond critique. Mistletoe is generally well tolerated,
with no or only minor side-effects. [14]
Mistletoe-prescribing physicians often observe a marked
improvement in fatigue after some months of mistletoe
application, and even use fatigue as an indicator for indi-
vidual adjustment of dosage. Nevertheless, CRF has not so
far been addressed as a primary objective in mistletoe
studies. [13,14,16] As a sub-dimension of QoL assess-
ment however, positive outcomes on fatigue were noted
([17] and Table 1). For instance, two studies evaluating in-
patient cancer treatment in AM hospitals (including mis-
tletoe therapy) observed a significant improvement in
fatigue levels. [18,19]
The following case, drawn from routine clinical practice,
describes a disease-free breast-cancer patient suffering
from severe CRF, who showed a remarkable response pat-
tern to the application of mistletoe extracts.
Case presentation
History and presenting condition
A 36-year-old Swedish woman with a history of recurrent
breast cancer and severe CRF presented at Vidarkliniken in
Sweden. Vidarkliniken provides integrated AM health care
[16,18] in an inpatient and outpatient setting, primarily
for patients with cancer, stress-related diseases and
chronic pain. The woman had been treated for breast can-
cer with positive axillary lymph nodes 10 years previously
(see Table 2 for details of anamnesis, findings and treat-
ment). Additional to surgical removal she had undergone
bilateral oophorectomy (as participant in a clinical trial),
and had received adjuvant radiotherapy and hormone
therapy which, however, was halted after 4 months
because of side effects. Eight years later she started suffer-
ing from extreme tiredness, and after one further year a
relapse was ascertained: a palpable sternum metastasis,
confirmed twice by ultrasound-guided fine-needle biopsy.
The metastasis was hormone receptor-negative in contrast
to her primary breast cancer. On computer tomography
two small changes in the lungs were considered as possi-
ble metastasis. The woman received palliative chemother-
apy which was halted after 5 cycles because of severe side
effects. Subsequently, she underwent radiotherapy of the
breastbone. Both treatments had good clinical and radio-
logical result: the sternum metastasis was no longer palpa-
ble, follow-up computer tomographies and skeletal
scintigrams showed complete remission. Subsequently no
further disease activity was observed, either radiologically
or clinically.
Eight months after radiation therapy, the patient attended
Vidarkliniken for 10 days of cancer rehabilitation. She was
suffering from reduced general condition, with migraine-
like headache, dizziness and diffuse pain throughout her
body. Fatigue had temporarily improved after radiation
therapy, but recurred after some months, having a strong
impact on her daily life and forcing her to rest several
times each day. Although she felt tired, she was physically
active, going for several walks a day with her dog. She slept
well and did not feel depressed or anxious. She was forget-
ful but had no difficulties in concentrating. Physical
examination (including sternum) and routine blood sam-
ples were normal. Concerning her social situation, she
lived as a single mother with her now 14-year-old son, as
was already the case at the time of her primary diagnosis
10 years previously. At that time she had experienced
some fatigue, but considered this was due to her life situ-
ation as a single mother raising a 4-year-old child. She had
no education after high school, and had some short-term
employment prior to relapse, being sick-listed since then.
Treatment
During rehabilitation, several AM treatments were applied
– medicines, art and physical therapies – and, in particu-
lar, a mistletoe treatment was initiated (Iscador® M).
The main goal of the mistletoe treatment was to improve
the patient's general condition, QoL and fatigue, and pos-
sibly exert a positive influence on the course of the cancer
disease. The mistletoe treatment followed mainly general
recommendations, i.e. subcutaneous Series 0, Series 1, or
Series 2 injections (Series 2 not used in this case): Series 0
means 7 injections at a lower dosage (2 × 0.01 mg/ml, 2 ×
0.1 mg/ml, 3 × 1 mg/ml); Series 1 means 7 injections at
higher dosage (2 × 0.1 mg/ml, 2 × 1 mg/ml, 3 × 10 mg/Cases Journal 2009, 2:77 http://www.casesjournal.com/content/2/1/77
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ml). Therapy starts with repeated injections of Series 0
(three injections per week, e.g. Monday, Wednesday, Fri-
day) for five weeks, followed by a one-week pause. After
this break, depending on the patient's response, either
Series 0 is repeated, or the next series commences. Treat-
ment modifications are geared to the patient's reactions
(general condition, specific symptoms, skin reaction): one
can switch between series; and one can prolong or shorten
the intervals within a series, or the pauses after the five-
week treatment cycles.
The treatment was well-tolerated by the patient. When
discharged from the clinic after 10 days she stated that she
felt physically stronger, inwardly calmer and had less
pain. After discharge, all other AM therapies and medi-
cines were terminated, but mistletoe therapy was contin-
ued at home.
Outcome
Mistletoe therapy continued for 3 years. As the patient
lived a long way from the clinic, further consultations and
follow-up were done by telephone. Timing of these con-
tacts was determined by the patient's needs, the intervals
Table 1: Clinical trials on mistletoe treatment of cancer that also evaluated influence on fatigue (secondary outcome measure).
Sample size Study type Primary study question Assessment of 
fatigue/tiredness
Results on fatigue/
tiredness*
Studies on mistletoe application
233 RCT
(mistletoe vs. Lentinan)
QoL TCM-score Improvement and 
advantage
(total TCM score 
significant)
272 RCT, double-blind
(mistletoe vs. placebo)
QoL (GLQ-8, Spitzer uniscale) 1) GLQ-8
2) EORTC QLQ-C30
1) Significant advantage
2) No differences of 
total score
352 RCT, double-blind
(mistletoe vs. placebo)
QoL (FACT-G) GLQ-8 Significant advantage
399 RCT, open
(mistletoe vs. no mistletoe)
Disease-free survival EORTC
QLQ-C30
No advantage
25 Phase II trial
(single-arm)
Tumor response Statement Improvement
804 Retrolective comparative 
epidemiological cohort study 
(mistletoe vs. no mistletoe)
Adverse drug reactions from 
conventional cancer drugs, disease 
symptoms, functional capacity, 
hospitalization
Statement Improvement and 
significant advantage
Retrolective comparative 
epidemiological cohort study 
(mistletoe vs. no mistletoe)
Adverse drug reactions from 
conventional cancer drugs, disease 
symptoms, functional capacity, 
hospitalization
Statement Improvement and 
significant advantage
1442 Retrolective comparative 
epidemiological cohort study 
(mistletoe vs. no mistletoe)
Adverse drug reactions from 
conventional cancer drugs
Statement Improvement and 
significant advantage
1248 Retrolective comparative 
epidemiological cohort study 
(mistletoe vs. no mistletoe)
Adverse drug reactions from 
conventional cancer drugs
Statement Significant advantage
Studies on whole-system AM care including mistletoe application
120 (44) Matched pair study 
(AM versus conventional care)
QoL EORTC
QLQ-C30
Improvement and small 
advantage
110 Sinlge-arm observational study QoL EORTC
QLQ-C30
Significant 
improvement
For references see [17].
* Improvement refers to pre-post difference; advantage refers to difference of pre-post-changes between comparison groups
Abbreviations: RCT: randomised controlled trial; QoL: Quality of life; AM: anthroposophic medicine; TCM: Traditional Chinese Medicine Index; 
GLQ-8: Global Quality of Life Scale; FACT-G: Functional Assessment of Cancer Therapy-General; EORTC QLQ-C30: European Organization for 
Research and Treatment Core Quality of Life Questionnaire.
Not considered were indirect measurement of fatigue/tiredness, e.g. "I am forced to spend time in bed". Not included are three studies that also 
used quality of life evaluation tools including questions on fatigue but that did not present any details on fatigue: two small comparative trials using 
EORTC QLQ-30, one of which reported an advantage, the other one not. One single-arm trial used SF-36 and reported an improvement.Cases Journal 2009, 2:77 http://www.casesjournal.com/content/2/1/77
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varying between weeks and months. At every contact, the
physician documented information on mistletoe dosage,
general condition and/or fatigue.
During this time, dosage of mistletoe extracts varied sub-
stantially. Changes of dosage were usually recommended
by the doctor, and recurring temporary treatment inter-
ruptions decided by the patient herself. The patient's rea-
sons for interruption were improvement of fatigue to a
satisfactory level, and her discomfort with ongoing anti-
cancer therapy despite being considered disease-free. Alto-
gether the patient reported a highly variable level of
fatigue and overall condition. A close correspondence
between mistletoe application, fatigue and general condi-
tion emerged. The common pattern was a worsening of
overall condition and fatigue during longer treatment
breaks or dose reductions, and an improvement after
restart or intensification of the mistletoe therapy.
For the timing (A, B, ...) of the following description, see :
Figure 1:
(A) Follow-up 3 months after rehabilitation period. After
a period of varying intensity of fatigue, and repeated per-
spiration during the initial weeks of mistletoe treatment,
the patient continued to inject mistletoe S0 and felt less
tired. Mistletoe dosage was now slightly decreased due to
local skin reactions.
Table 2: Anamnesis, findings and treatment.
Age State of disease Treatment
26 Diagnosis: Left breast cancer, 1.2 cm
Histology: moderately differentiated, ductal invasive, Elston-Ellis grade 
II, estrogen receptor positive, progesterone receptor pos, S-phase 
impossible to calculate, 2 of 18 axillary lymphnodes positive, no 
extranodal growth, benign ovaries
TNM-classification: pT1 pN1 pM0
Surgery
• Local surgery, not radical
• Quadrant resection and axillary surgery, radical
• Bilateral oophorectomy
Radiotherapy: Local 50 Gy, 2 Gy × 25
Hormone therapy: Tamoxifen 20 mg/day, stopped after 4 months 
due to side effects 
(bad mood, lower capacity, sensitivity to noise – the symtoms 
disappeared when therapy was stopped)
34 Onset of severe fatigue
35 Relapse: bone metastasis of breast cancer in sternum, verified by 2 
fine-needle biopsies, hormone receptor negative, MIB-1 30%, HER-2 
neg. On computer tomography two changes in lungs measuring 6 
mm, considered as possible metastasis
Complete radiological and clinical remission
Palliative chemotherapy: FEC-60 (Fluorouracil, Epirubicin, 
Cyclophosphamide) stopped after 5 cycles due to side effects 
(headache, nausea, pain, anxiety)
Radiotherapy: Breast bone 39 Gy, 13 Gy × 3
Diffuse pain especially in knees Bisphosphonates, stopped by patient after one month because of 
lack of improvement
Reduced fatigue for some months after chemo- and radiotherapy
36 Severe fatigue 10-day rehabilitation in an AM hospital Start of mistletoe 
treatment
36–38 Fatigue of varying intensity
Relapse-free
Mistletoe treatment: Individually adapted dosage and repeated 
breaks (see text and : Figure 1)
Changes in mistletoe dosage, fatigue and general condition (pain, nausea, mood, headache) Figure 1
Changes in mistletoe dosage, fatigue and general condition (pain, nausea, mood, headache).  ‚ - improvement 
of symptoms, ‰ - worsening of symptoms, → - no change of symptoms.   S0 – Series 0, S1 – Series 1. Letters (A, B, ≡) refer 
to description in text.  
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(B) She reported halting mistletoe injections at her own
decision for some weeks, during which she experienced an
impairment of her general condition. After restarting the
injections, conditions improved: she felt stronger, suf-
fered less headache, no longer had nausea and felt less
fatigue. She was satisfied with her overall condition. Mis-
tletoe dosage was now increased from S0 to S1 because of
good clinical effect.
(C) She described improved fatigue symptoms as well as
better general condition throughout the two months fol-
lowing the last dosage increase. The mistletoe dosage was
now decreased from S1 to S0 due to local skin reactions.
(D) She reported that she felt "lifeless" on the lowered
dosage S0, and that she had increased general pain. The
dosage was now increased to S1.
(E) Next contact after 5.5 months. She reported a better
general condition on the higher dosage, but she felt tired
on days without mistletoe. The dosage was left
unchanged.
(F) She lowered the overall dosage by changing the
scheme at her own discretion, taking one-week breaks
after every series instead of after every second series. She
reported worsening of general condition (pain, nausea,
fatigue) during these one-week breaks. General condition
and fatigue always improved significantly during subse-
quent injection periods. In : Figure 1 only one such break
is shown to illustrate the correlation. She even noticed a
pattern of increasing fatigue on Sundays, and regular
improvement of her fatigue on Mondays (injection days
Monday, Wednesday and Friday). The mistletoe dosage
was now increased by shortening the breaks after every
series, from one week to 4 days.
(G) She reported that she felt depressed during longer
breaks in mistletoe treatment. After restart, she recovered
totally to her former level. Unfortunately, there was no
documentation of length and number of these longer,
patient-initiated breaks. In : Figure 1 only one such break
is shown to illustrate the correlation.
(H) She halted mistletoe injections at her own discretion
for two weeks: during this time she felt bad, trembled
from physical effort when walking with her dog, and had
less energy and more nausea. These symptoms disap-
peared after restart of the injections, and she again felt as
she did before the interruption to treatment.
Altogether, the patient's fatigue could never be resolved
completely, her overall capacity remained low, and she
remained on sickness benefit. Psychologically, she strug-
gled with the conflicting status of having been in an incur-
able, palliative state of disease and subsequently being
considered disease-free. Continuing to use a cancer ther-
apy (mistletoe extracts) contributed to her confusion, and
as, due to her severe fatigue, she did not feel well, she was
unsure what to believe.
After 30 months her general condition worsened, with
severe back pain, stomach ache, and weight loss. This
raised the suspicion of breast-cancer recurrence, but after
several radiological and clinical investigations, as well as
blood samples, the patient was still considered to be in
complete remission. She finally halted mistletoe treat-
ment after a total of 36 months. The reasons for this were:
increased perspiration after dose intensification, her
ongoing uneasiness with the continued application of a
cancer remedy, the dissuasive attitude of her oncologists,
and the fact that her family doctor had initiated an inten-
sive treatment program, with physiotherapy and a com-
bined form of occupational and cognitive therapy, in
order to help her back to work. This new approach made
her feel totally exhausted, and without energy for any-
thing else. Unfortunately, this approach has not so far
achieved the desired result.
Differential diagnoses and concomitant therapies
The diagnosis of CRF was confirmed according to the
ICD-10 criteria (Table 3) [4,5]: 11 of the 13 criteria were
met, including the main criterion A1. (For confirmation,
6 of the 13 ICD10-criteria including A1 have to be ful-
filled [4].)
Other diagnoses potentially leading to severe fatigue were
largely excluded: no signs of major depression were ever
revealed by the patient during the whole observation
period. Also, in a formal assessment using the Mont-
gomery-Åsberg Depression Rating Scale (MADRS-S), she
received 12 out of a possible score of 54, 11 being the "no
depression" limit [20]; and in a structured telephone
interview following DSM IV criteria for major depression,
she did not present depressive symptoms. The patient was
in a difficult life situation, and psychological effects prob-
ably contributed to her fatigue and general condition.
Nevertheless, the patient's overall psychosocial situation
was largely stable and therefore did not explain the highly
variable fluctuations in her condition. There was also no
reason to suspect any further specific psychological distress
underlying the fatigue [5]. Nor were there signs of chronic
fatigue syndrome or burn-out syndrome. Hormonally induced
fatigue – early menopause due to oophorectomy – was
unlikely due to lack of a temporal link: fatigue started
seven years later. Radiation-induced cardiomyopathy causing
fatigue was also excluded: fatigue had started one year
before radiation of the sternum and an echocardiogram
two years after radiation showed normal findings.
Hypothyroidism and anemia were also repeatedly excludedCases Journal 2009, 2:77 http://www.casesjournal.com/content/2/1/77
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The patient used vitamin B12 preparations from time to
time and at her own decision, but did not experience any
change in fatigue correlating with its use. In fact, vitamin
B12 deficiency was detected after the observation period,
but after successful vitamin B12 substitution no change in
fatigue was observed. The various treatments applied dur-
ing rehabilitation at the AM hospital were all discontin-
ued after discharge. The patient did not have a specific
exercise program, but went on several walks each day on
her own initiative. This, however, did not correlate with
the fatigue.
Discussion
This case is striking because, during a two-and-a-half-year
observation period, the patient spontaneously reported
highly fluctuating levels of fatigue and general condition
that corresponded to the application and dosage of mis-
tletoe treatment: dose reductions (prescribed by the phy-
sician) and therapy breaks (decided by the patient) were
usually followed by a worsening of fatigue and/or general
condition, while increase in dosage or restarting of treat-
ment led to improvement in fatigue and better general
condition.
The explanation for these observations can only be hypo-
thetical at the current status of knowledge. Mistletoe ther-
apy has often been reported to improve QoL. [13,14] A
number of clinical studies that investigated the influence
of mistletoe on QoL also raised the topic of fatigue, and
most showed positive results (see Table 1); none of them,
however, assessed CRF in D-FCP. The biological factors
involved in the modification of fatigue can only be a sub-
ject of speculation mainly because the mechanisms
responsible for CRF are largely unknown. Endorphins
might be involved, since these are enhanced by mistletoe
applications; or the cytokine network, which is also influ-
enced by mistletoe extracts (overview see [13,15]). How-
ever, other or multiple factors, including more
psychological ones, could also be involved.
Irrespective of any causal explanation, the observations in
this case are clinically relevant. Fatigue is a major and
unsolved problem in and after cancer disease and has a
profound effect on QoL. [1,3] It is one of the most com-
mon unrelieved symptoms in the cancer context, and
affects patients significantly and extensively, more than
any other symptom such as anxiety, pain, nausea/vomit-
ing, hair loss, depression, alopecia, etc. [3,21] Patients feel
that fatigue is the biggest problem. It affects central aspects
of their lives such as the ability to work, to take care of the
family, to have relationships with friends, and to enjoy
life. [3] Given the magnitude of the problem, it is aston-
ishing that research on CRF is so underdeveloped. Treat-
ment options are limited: they are mainly behavioral,
involving exercises and psychosocial interventions, but
also some medication. Such treatments do show positive
results in reducing fatigue, but with limited clinical signif-
icance for the individual patient, and do not seem to be of
sufficient help to all patients. Their effect on fatigue in D-
FCP largely remains an open question. [6,11,12]. There is
an urgent need, therefore, to find further therapy options.
The observations presented here should be interpreted in
their context; the case derives from daily practice, and was
not specially designed for subsequent reporting. It has
major limitations, especially insofar as no well-estab-
lished questionnaire was used to assess the fluctuations
on fatigue and its impact on daily life. Several validated,
sophisticated, multidimensional methods would be avail-
able to assess fatigue; they are, however, primarily
Table 3: Draft ICD-10 criteria for CRF. 
A1 Significant fatigue, diminished energy, or increased need to rest, disproportionate to any recent change in activity level
A2 Complaints of generalised weakness or limb heaviness
A3 Diminished concentration or attention
A4 Decreased motivation or interest to engage in usual activities
A5 Insomnia or hypersomnia
A6 Experience of sleep as unrefreshing or nonrestorative
A7 Perceived need to struggle to overcome inactivity
A8 Marked emotional reactivity (e.g., sadness, frustration, or irritability) to feeling fatigued
A9 Difficulty completing daily tasks attributed to feeling fatigued
A10 Perceived problems with short-term memory
A11 Postexertional malaise lasting several hours
B The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
C There is evidence from the history, physical examination or laboratory findings that the symptoms are a consequence of cancer or cancer 
therapy
D The symptoms are not primarily a consequence of comorbid psychiatric disorders such as major depression, somatization disorder, 
somatoform disorder, or delirium
CRF is diagnosed when six (or more) of the symptoms above have been present everyday or nearly every day during the same two-week period in 
the past month, and at least one of the symptoms is significant fatigue (A1) [4,5].Cases Journal 2009, 2:77 http://www.casesjournal.com/content/2/1/77
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designed as research tools, and are difficult to use in clin-
ical practice [2,6]. For routine use, only simple questions
can be a guide for approximately estimating the extent of
fatigue and its impact over time (for instance see Table 4).
[22] No matter what assessment method is chosen, ulti-
mately one always has to rely on the patient's own report.
The medical information provided in this instance
should, therefore, sufficiently facilitate a pragmatic judge-
ment of the case history.
One could object that the doctor's prescription may have
influenced the patient's expectations and affected her
experience of fatigue and general condition. It was how-
ever generally the patient herself who decided to stop the
treatment when she felt better, and when she felt stressed
by the psychological conflict of using a cancer medicine
while considered disease-free. But despite these strong
motives, she restarted treatment each time at her own ini-
tiative. The effect of a reporting bias on the outcome over
more than two years therefore seems to be of minor rele-
vance. Furthermore, the substantial impact and consistent
distress of CRF makes it unlikely that it can easily be
improved by mere suggestion from the doctor. In addi-
tion, reviews of clinical trials found little or no improve-
ments of QoL and of performance status in cancer patients
due to suggestive placebo effects. [23]
The presented case offers insight into routine care of a can-
cer patient with fatigue, and her spontaneously reported
impressions. In this respect the case report presents infor-
mation usually not documented in controlled clinical tri-
als: the patient's suffering, persistence of the fatigue, the
misery of its seeming incurability, reduced quality of life,
inability to work, and the multidimensional aspects of the
situation. Controlled trials on fatigue hardly ever describe
these dimensions, although these are essential for patient
care. For instance, the RCTs on pharmacological and non-
pharmacological interventions in CRF have usually short
observation periods; they do not assess long-lasting
improvement or even cure, but only, at best, short-term
amelioration with limited clinical significance for the
individual patient; and they concentrate on fatigue in the
context of chemotherapy, radiotherapy or surgery, or in
the palliative situation. No conclusions can be drawn
from these RCTs about how to treat disabling CRF in dis-
ease-free cancer patients (independent of cancer treat-
ments) so as to provide sufficient relief and restoration of
normal functioning. [11,12]
Unfortunately, fatigue never disappeared completely in
our patient, and fully returned after final discontinuation
of mistletoe application. This did however facilitate obser-
vation of pattern correspondences. The therapeutic effect
of mistletoe seems quite remarkable, considering that no
curative and only limited alleviating options appear to
exist. From an AM healthcare perspective, the long-dis-
tance consultation in this case has to be regarded as sub-
optimal; personal contact is considered to be vital and
could perhaps have enabled more extensive support from
the multimodal AM treatment approach – for instance by
drawing on art therapy [24] and physical interventions –
which might have contributed to more profound
improvement.
Future studies on mistletoe treatment of cancer should
investigate possible influences on fatigue, especially in D-
FCP, using well established fatigue evaluation tools (e.g.
[2,6,25]). Analyses should include questions relating to
dosage, treatment pause, preparation, and accompanying
therapies. When designing relevant studies, one should
remember that mistletoe injections sometimes induce
short-term tiredness as part of a mild and dose-depend-
ent, flu-like side effect. [13] Besides treatment superiority
in comparative trials, adequate and sustained ameliora-
tion of the condition of the individual patient should also
be carefully investigated. If this theme is to be addressed
by the general physician in routine daily practice, height-
ened awareness and specific documentation (specific
questions (Table 4), VAS, diary, etc.) might be useful for
recording important observations (e.g. [22]). As CRF is a
complex phenomenon, multimodal approaches includ-
ing non-pharmacological treatments might be more effec-
tive than single remedies. This should also be taken into
account in further research.
Conclusion
Mistletoe treatment showed an effect on the severity of
CRF symptoms. As CRF is a major complaint in cancer
patients, for which few therapeutic options are available,
these observations should be investigated further. Possi-
ble effects of multimodal treatment approaches should
also be clarified.
Consent
The patient was in full agreement with publication of her
case and she read the final version of the paper. Written
informed consent was obtained from the patient for pub-
lication of this case report. A copy of the written consent
is available for review by the Editor-in-Chief of this jour-
nal.
Table 4: Questions for assessment of fatigue severity and impact 
over time in routine practice setting with limited time for 
evaluation [22].
1. Are you experiencing any fatigue?
2. If so, how severe has it been, on average, during the past week? 
(A simple 0–10 rating scale can be used, i.e. 0–3: mild fatigue, 4–6: 
moderate fatigue, 7–10 severe fatigue)
3. How does fatigue interfere with your ability to function?Publish with BioMed Central    and   every 
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